HK1148202A1 - Pharmaceutical solutions, process of preparation and therapeutic uses - Google Patents

Pharmaceutical solutions, process of preparation and therapeutic uses

Info

Publication number
HK1148202A1
HK1148202A1 HK11102314.2A HK11102314A HK1148202A1 HK 1148202 A1 HK1148202 A1 HK 1148202A1 HK 11102314 A HK11102314 A HK 11102314A HK 1148202 A1 HK1148202 A1 HK 1148202A1
Authority
HK
Hong Kong
Prior art keywords
preparation
therapeutic uses
pharmaceutical solutions
pharmaceutical
solutions
Prior art date
Application number
HK11102314.2A
Other languages
English (en)
Inventor
Eric Schenkel
Claire Poulain
Bertrand Dodelet
Domenico Fanara
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1148202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of HK1148202A1 publication Critical patent/HK1148202A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
HK11102314.2A 2008-03-03 2011-03-08 Pharmaceutical solutions, process of preparation and therapeutic uses HK1148202A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08003915 2008-03-03
PCT/EP2009/052454 WO2009109547A1 (en) 2008-03-03 2009-03-02 Pharmaceutical solutions, process of preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
HK1148202A1 true HK1148202A1 (en) 2011-09-02

Family

ID=39643757

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102314.2A HK1148202A1 (en) 2008-03-03 2011-03-08 Pharmaceutical solutions, process of preparation and therapeutic uses

Country Status (21)

Country Link
US (1) US20110021786A1 (de)
EP (1) EP2273975B8 (de)
JP (6) JP2011513360A (de)
KR (1) KR101353425B1 (de)
CN (1) CN101945647B (de)
AU (1) AU2009221177B2 (de)
BR (1) BRPI0908421C1 (de)
CA (1) CA2715685C (de)
CY (1) CY1115254T1 (de)
DK (1) DK2273975T3 (de)
EA (1) EA018736B1 (de)
ES (1) ES2474945T3 (de)
HK (1) HK1148202A1 (de)
HR (1) HRP20140634T1 (de)
IL (1) IL207558A (de)
MX (1) MX2010009222A (de)
PL (1) PL2273975T3 (de)
PT (1) PT2273975E (de)
RS (1) RS53418B (de)
SI (1) SI2273975T1 (de)
WO (1) WO2009109547A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2273975T3 (pl) * 2008-03-03 2014-09-30 Ucb Pharma Sa Roztwory farmaceutyczne, sposoby wytwarzania i zastosowania terapeutyczne
CN107243007A (zh) * 2008-10-16 2017-10-13 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
PT2358361T (pt) 2008-11-18 2016-11-18 Ucb Biopharma Sprl Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina
DK2790695T3 (en) 2011-12-16 2016-04-18 Uni Pharma Kleon Tsetis Pharmaceutical Lab S A A pharmaceutical composition comprising (S) -2- (2-oxopyrrolidin-1-yl) butanamide
CN102525900A (zh) * 2012-01-19 2012-07-04 南京恒道医药科技有限公司 左乙拉西坦注射液及其制备方法
MX2014012461A (es) * 2012-04-19 2015-01-12 Bard Inc C R Soluciones intravenosas con estabilidad de ph mejorada bajo esterilizacion con oxido de etileno.
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
CN103550143B (zh) * 2013-10-19 2019-05-14 浙江华海药业股份有限公司 一种左乙拉西坦注射液的制备方法
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
UA127826C2 (uk) 2016-05-18 2024-01-17 Локсо Онколоджі, Інк. СПОСІБ ОДЕРЖАННЯ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-а]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
CN106491523A (zh) * 2016-09-24 2017-03-15 北京万全德众医药生物技术有限公司 一种布瓦西坦口服溶液及其制备方法
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
US20210393588A1 (en) * 2018-11-02 2021-12-23 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
US20220187503A1 (en) 2019-03-28 2022-06-16 Toyobo Co., Ltd. Anti-reflection circular polariser and image display device using same
CN113908120A (zh) * 2021-09-30 2022-01-11 北京诺康达医药科技股份有限公司 布立西坦药物溶液及其制备方法
CN114213306A (zh) * 2021-12-28 2022-03-22 海南鑫开源医药科技有限公司 一种布瓦西坦酸杂质的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US7612215B2 (en) * 2004-06-11 2009-11-03 Ucb Pharma, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
EP1731149A1 (de) * 2005-06-08 2006-12-13 Ucb S.A. Verwendung von Brivaracetam in der Behandlung von Krankheiten, die durch vorschreitende Myoloniusepilepsie gekenneichnet sind
PL2273975T3 (pl) * 2008-03-03 2014-09-30 Ucb Pharma Sa Roztwory farmaceutyczne, sposoby wytwarzania i zastosowania terapeutyczne
KR101286540B1 (ko) * 2008-04-16 2013-07-17 엘지디스플레이 주식회사 액정표시장치

Also Published As

Publication number Publication date
HRP20140634T1 (hr) 2014-11-21
CA2715685A1 (en) 2009-09-11
ES2474945T3 (es) 2014-07-10
JP2015145382A (ja) 2015-08-13
PL2273975T3 (pl) 2014-09-30
SI2273975T1 (sl) 2014-09-30
RS53418B (en) 2014-12-31
JP2020128384A (ja) 2020-08-27
WO2009109547A1 (en) 2009-09-11
EP2273975A1 (de) 2011-01-19
JP2022169734A (ja) 2022-11-09
BRPI0908421B1 (pt) 2020-08-04
JP2011513360A (ja) 2011-04-28
EA201001402A1 (ru) 2011-06-30
CA2715685C (en) 2015-04-28
AU2009221177A1 (en) 2009-09-11
IL207558A0 (en) 2010-12-30
EA018736B1 (ru) 2013-10-30
BRPI0908421B8 (pt) 2020-08-18
IL207558A (en) 2015-02-26
JP2017114890A (ja) 2017-06-29
BRPI0908421A2 (pt) 2015-08-04
EP2273975B8 (de) 2014-12-17
PT2273975E (pt) 2014-07-17
BRPI0908421C1 (pt) 2021-05-25
AU2009221177B2 (en) 2013-05-30
US20110021786A1 (en) 2011-01-27
CN101945647B (zh) 2013-01-09
DK2273975T3 (da) 2014-06-30
MX2010009222A (es) 2010-09-28
CY1115254T1 (el) 2017-01-04
CN101945647A (zh) 2011-01-12
KR20100126466A (ko) 2010-12-01
EP2273975B1 (de) 2014-04-09
JP2019089837A (ja) 2019-06-13
KR101353425B1 (ko) 2014-02-18

Similar Documents

Publication Publication Date Title
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
MX342643B (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
PH12013502192A1 (en) Antibodies against human angiopoietin 2
HK1140940A1 (en) Titration of tapentadol
WO2010087947A3 (en) Transdermal delivery of diclofenac, carbamazepine and benzydamine
IN2012DN02805A (de)
MX2011007930A (es) Conjugados de insulina cristalina.
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
IN2014CN02616A (de)
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
ZA200906853B (en) Aqueous hydrogen peroxide solution, process for its preparation and use thereof
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
UA96574C2 (ru) Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции
UA89010C2 (ru) Комбинированное обезболивающее средство на основе кеторолака и дротаверина
WO2010139411A3 (de) 17β-ALKYL-17α-OXY-ESTRATRIENE
UA92646C2 (ru) применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием
UA48243U (uk) Фармацевтична композиція
JO2775B1 (en) 3-indazolil 4-pyridyl isothiazole
UA106224C2 (en) Crystalline insulin-conjugates